Press release BoxID: 135745 (Evotec AG)
  • Evotec AG
  • Manfred Eigen Campus, Essener Bogen 7
  • 22419 Hamburg
  • Contact person
  • Anne Hennecke
  • +49 (40) 56081-286

Evotec to Report Third Quarter Results on 13 November 2007

Hamburg, Germany | Oxford, UK – Evotec AG (Frankfurt Stock Exchange: EVT) will report its financial results for the third quarter of 2007 on Tuesday, 13 November 2007

(PresseBox) (Hamburg, ) The Company is going to hold a conference call to discuss the results:

Conference call details:
Date: Tuesday, 13 November 2007
Time: 02.00 p.m. CET
01.00 p.m. GMT
08.00 a.m. US time (East Coast)

Conference call numbers:
Europe: +49.(0)69.5007 1308 (Germany)

+44.(0)20.7806 1955 (UK)
US: +1.718.354 1389
Pass Code: 4882161

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.22222 0418 (Germany) or +44.(0)20.7806 1970 (UK) and in the US by +1.718.354 1112. The access code is 4882161#. The on-demand version of the webcast will be available on our website: - Investors – Financial Reports.

Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs.

Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development:

EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.